Teva shares sinking

It was a terrible day for Teva's shares on  TASE.  Teva's stock is now trading at near historical lows from a forward-looking P/E perspective.

Ajovy , comes with bright expectatives but there are already alternative and largely generic drugs to treat migraine, meaning that getting insurers to cover more expensive anti-CGRP treatments, even for patients who have failed existing therapies, is going to be tough. Teva's Huntington's disease medicine Austedo is expected to contribute significantly. Over the past two years, Teva has also managed to slash around $7 billion from its total outstanding debt. All told, Teva seems to be nearing an inflection point on several fronts. 

But the bourse thinks differently. I have lots and lots of shares.....